ERYtech Pharma Announces Completion of Enrollment of a Phase II Clinical Trial for GRASPA(R) in First-Line for Elderly Patients with Acute Lymphoblastic Leukaemia

LYON,France & PHILADELPHIA, Pa.--(BUSINESS WIRE)--ERYtech Pharma announces the early completion of the enrollment and safety follow-up a Phase II clinical trial for GRASPA®. This open-labeled trial (GRASPALL-GRAALL SA2 2008) introduced GRASPA® in a first-line treatment for Acute Lymphoblastic Leukemia (ALL) in patients older than 55 years. The clinical end point combines safety and efficacy parameters. The trial enrolled 30 patients and involved 54 investigation centers, all being members of the “Group for Research on Adult Acute Lymphoblastic Leukemia” (GRAALL). The company expects to have safety and efficacy data from this study in the third quarter of 2011.